ArticleFrontiers in endocrinology2025
Sustained testosterone suppression: prognostic indicator in advanced hormone sensitive prostate cancer.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to investigate the relationship between sustained testosterone suppression and clinical outcomes in advanced hormone-sensitive prostate cancer (aHSPC), which integrates longitudinal testosterone with castration duration to predict tumor progression and prognosis. Methods: In this retrospective study, we analyzed 336 patients with aHSPC from two medical centers who underwent serial testosterone monitoring during androgen deprivation therapy (ADT). The patients were stratified by testosterone suppression sustainability into the testosterone sustained response and testosterone non-sustained response groups. We evaluated the baseline characteristics, time to progression (TTP), and the survival outcomes between groups. Results: The cohort demonstrated a median TTP of 18 months and an overall survival of 6.17 years. Patients in the testosterone sustained response group showed significantly better outcomes than those in the testosterone non-sustained response group, with longer median survival (7.58 Conclusion: Sustained testosterone suppression provides a clinically applicable method for assessing treatment efficacy and predicting prognosis in aHSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.